| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,291 |
1,285 |
$85K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,378 |
1,284 |
$64K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
601 |
595 |
$29K |
| 99358 |
Prolong nursin fac eval 15m |
615 |
604 |
$12K |
| 99205 |
Prolong outpt/office vis |
206 |
206 |
$12K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
379 |
363 |
$12K |
| 99215 |
Prolong outpt/office vis |
133 |
130 |
$6K |
| 94760 |
|
1,688 |
1,624 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
421 |
408 |
$6K |
| 99070 |
|
301 |
287 |
$2K |
| 99000 |
|
461 |
445 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
99 |
95 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
106 |
102 |
$1K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
31 |
30 |
$741.93 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
32 |
30 |
$562.59 |
| 81002 |
|
241 |
239 |
$339.66 |
| 81000 |
|
59 |
58 |
$87.72 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15 |
15 |
$77.52 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
14 |
$1.52 |
| 3074F |
|
35 |
35 |
$0.00 |
| 99443 |
|
32 |
31 |
$0.00 |
| 3008F |
|
68 |
66 |
$0.00 |
| 99072 |
|
333 |
323 |
$0.00 |
| 99051 |
|
527 |
517 |
$0.00 |
| 3078F |
|
34 |
34 |
$0.00 |